Skip to main navigation

Investors

News Archive
Past Events and Presentations
Stock History

News Archive

News Archive

Items Per Page

Year

Mar 10, 2011

Standard & Poor's Upgrades Mylan

Mar 10, 2011

Mylan's Matrix Receives FDA Approval Under PEPFAR for Zidovudine Tablets, 100 mg

Mar 01, 2011

Mylan Confirms First-to-File Patent Challenge Relating to Vivelle-Dot®

Mar 01, 2011

Robert J. Cindrich and Heather Bresch Appointed to Mylan's Board of Directors

Feb 28, 2011

Mylan Receives Approval for Generic Version of Neurontin® Capsules

Feb 24, 2011

Mylan Files Annual Report on Form 10-K for Year Ended Dec. 31, 2010

Feb 24, 2011

Mylan Reports Adjusted Diluted EPS of $0.45 for the Quarter, a 36% Increase over Prior Year Quarter; and $1.61 for the Year, a 24% Increase over Prior Year

Feb 15, 2011

Mylan Launches First Generic Version of Vfend® Tablets

Feb 11, 2011

Mylan Schedules Fourth Quarter 2010 Financial Results Conference Call and Live Webcast

Jan 28, 2011

Mylan Receives Approval for First-to-File Generic Sular® Extended-Release Tablets

Pagination

First page
Previous page
…
Page 71
Page 72
Page 73
Page 74
Current page 75
Page 76
Page 77
Page 78
Page 79
…
Next page
Last page

Share

Utility Nav

Privacy Statement
Terms and Conditions

©2025 Mylan N.V. All rights reserved. The Mylan logo is a registered trademark of Mylan Inc.